A new bill is now effective in the UK which aims to improve regulation for medical devices and ensure patient safety, as well as allow hospitals to develop personalised medicines.
List view / Grid view
Filter the results
7 February 2020 | By OSIsoft
Trustworthiness in data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development. Hear the latest findings from OSIsoft’s research in our upcoming webinar.
A survey of industry professionals states they expect immuno-oncology therapies and personalised medicines to continue to shape the pharmaceutical industry in the coming year.
The FDA has authorised the first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customise their diabetes management.
Functional links between metabolic, cardiovascular and renal diseases, as well as a focus on digital and a personalised approach will shape diabetes drug development in 2020, says new analysis.
Drones that transport medicines to emergency situations, urban environments or geographically-challenging locations are increasingly being utilised to improve delivery, however, there are few studies on their impact on drug stability. Here, Paul Royall and Patrick Courtney explore the implications of drone delivery on the safety and quality of medicines.
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
So-called 'nanodiamonds' could serve as a platform for diagnostic and therapeutic approaches for neurodegenerative diseases.
7 August 2019 | By WITec GmbH
This webinar describes how Raman microscopy can help solve some of the most vital and challenging questions that researchers face in 3D imaging and microparticle analyses of food, pharmaceuticals and microplastics, along with providing measurement examples from each field.
A team at the Technical University of Munich have made it possible for nano particles to be released in sequence with the use of artificial DNA.
At PQE Group we foster innovation, efficiency and quality services for sustainable regulated compliance solutions.
A new clinical trial will determine if monthly injections of anti-viral drugs are more effective at suppressing the HIV virus than daily pills.
The Almac Group, a CDMO serving the pharmaceutical and biotech sectors globally, is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities...
A clinical trial could be the world's first to look at personalised medicine in prostate cancer, with patients taking a therapy based on their DNA markers...